Burnett, A., Cavenagh, J., Russell, N., Hills, R., Kell, J., Jones, G., Nielsen, O. J., Khwaja, A., Thomas, I., Clark, R. and on behalf of the UK NCRI AML Study Group (2016) “Defining the dose of gemtuzumab ozogamicin in combination with induction chemotherapy in acute myeloid leukemia: a comparison of 3 mg/m2 with 6 mg/m2 in the NCRI AML17 Trial”, Haematologica. Pavia, Italy, 101(6), pp. 724-731. doi: 10.3324/haematol.2016.141937.